Randomized Trialhigh evidence
1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
Lancet (London, England)·July 15, 2026·PMID 42456692
Why it mattersBalancing thrombotic and bleeding risks after PCI in patients with atrial fibrillation is a common clinical challenge. This trial provides evidence that a very short 1-month dual therapy regimen can maintain efficacy while substantially lowering bleeding, supporting a strategy that may simplify post-PCI management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled